US FDA in project to assess LASIK side effects; issues warnings to 17 centres
This article was originally published in RAJ Devices
The US Food and Drug Administration has teamed up on a project with the Department of Defense and the National Eye Institute to assess how many patients undergoing LASIK (laser-assisted in situ keratomileusis) go on to experience adverse effects from the vision correction procedure1.
You may also be interested in...
Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.
Uncertainties over clinical and cost effectiveness are behind the health technology assessment body’s recommendation against Spravato's use on the National Health Service.
New medicines under evaluation at the European Medicines Agency.